AlzeCure Pharma AB has published an updated English company presentation.
The presentation, produced by FinWire, provides an updated view from CEO Martin Jönsson following collaboration and outlicensing agreements with US-based Eli Lilly and Denmark-based QuantumCell ApS relating to AlzeCure’s Alzheimer’s programs. The slides are available on demand.
AlzeCure develops small-molecule drug candidates for central nervous system diseases, focusing on Alzheimer’s disease and pain, and is advancing multiple candidates across three research platforms: NeuroRestore, Alzstatin, and Painless.
The company is listed on Nasdaq First North Premier Growth Market, and FNCA Sweden AB is its certified adviser.
